These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 39045273

  • 1. Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report.
    Barbaro D, Forleo R, Profilo MA, Lapi P, Giani C, Torregrossa L, Macerola E, Materazzi G.
    Front Endocrinol (Lausanne); 2024; 15():1389294. PubMed ID: 39045273
    [Abstract] [Full Text] [Related]

  • 2. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.
    Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Gule-Monroe MK, Williams MD, Sturgis EM, Goepfert RP, Gross ND, Lai SY, Gunn GB, Phan J, Rosenthal DI, Fuller CD, Morrison WH, Iyer P, Cabanillas ME.
    Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771
    [Abstract] [Full Text] [Related]

  • 3. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
    Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, Rassner M, Boerries M, Zielke A, la Rosee P, Meyer PT, Kroiss M, Weißenberger C, Schumacher T, Metzger P, Weiss H, Smaxwil C, Laubner K, Duyster J, von Bubnoff N, Miething C, Thomusch O.
    Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
    [Abstract] [Full Text] [Related]

  • 4. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.
    Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME.
    Thyroid; 2018 Jan; 28(1):79-87. PubMed ID: 29161986
    [Abstract] [Full Text] [Related]

  • 5. Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma.
    Cabanillas ME, Ferrarotto R, Garden AS, Ahmed S, Busaidy NL, Dadu R, Williams MD, Skinner H, Gunn GB, Grosu H, Iyer P, Hofmann MC, Zafereo M.
    Thyroid; 2018 Jul; 28(7):945-951. PubMed ID: 29742974
    [Abstract] [Full Text] [Related]

  • 6. Mutation-based, short-term "neoadjuvant" treatment allows resectability in stage IVB and C anaplastic thyroid cancer.
    Maurer E, Eilsberger F, Wächter S, Riera Knorrenschild J, Pehl A, Holzer K, Neubauer A, Luster M, Bartsch DK.
    Eur Arch Otorhinolaryngol; 2023 Mar; 280(3):1509-1518. PubMed ID: 36637521
    [Abstract] [Full Text] [Related]

  • 7. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.
    Hamidi S, Iyer PC, Dadu R, Gule-Monroe MK, Maniakas A, Zafereo ME, Wang JR, Busaidy NL, Cabanillas ME.
    Thyroid; 2024 Mar; 34(3):336-346. PubMed ID: 38226606
    [Abstract] [Full Text] [Related]

  • 8. Mutation based approaches to the treatment of anaplastic thyroid cancer.
    McCrary HC, Aoki J, Huang Y, Chadwick B, Kerrigan K, Witt B, Hunt JP, Abraham D.
    Clin Endocrinol (Oxf); 2022 May; 96(5):734-742. PubMed ID: 35067961
    [Abstract] [Full Text] [Related]

  • 9. A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan.
    Tahara M, Kiyota N, Imai H, Takahashi S, Nishiyama A, Tamura S, Shimizu Y, Kadowaki S, Ito KI, Toyoshima M, Hirashima Y, Ueno S, Sugitani I.
    Thyroid; 2024 Apr; 34(4):467-476. PubMed ID: 38343359
    [Abstract] [Full Text] [Related]

  • 10. Combination BRAFV600E Inhibition with the Multitargeting Tyrosine Kinase Inhibitor Axitinib Shows Additive Anticancer Activity in BRAFV600E-Mutant Anaplastic Thyroid Cancer.
    Gunda V, Ghosh C, Hu J, Zhang L, Zhang YQ, Shen M, Kebebew E.
    Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898
    [Abstract] [Full Text] [Related]

  • 11. Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study.
    Zhao X, Wang JR, Dadu R, Busaidy NL, Xu L, Learned KO, Chasen NN, Vu T, Maniakas A, Eguia AA, Diersing J, Gross ND, Goepfert R, Lai SY, Hofmann MC, Ferrarotto R, Lu C, Gunn GB, Spiotto MT, Subbiah V, Williams MD, Cabanillas ME, Zafereo ME.
    Thyroid; 2023 Apr; 33(4):484-491. PubMed ID: 36762947
    [Abstract] [Full Text] [Related]

  • 12. Case report: Complete response of an anaplastic thyroid carcinoma patient with NRAS Q61R/BRAF D594N mutations to the triplet of dabrafenib, trametinib and PD-1 antibody.
    Gui L, Zhu Y, Li X, He X, Ma T, Cai Y, Liu S.
    Front Immunol; 2023 Apr; 14():1178682. PubMed ID: 37122752
    [Abstract] [Full Text] [Related]

  • 13. Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report.
    Luongo C, Porcelli T, Sessa F, De Stefano MA, Scavuzzo F, Damiano V, Klain M, Bellevicine C, Matano E, Troncone G, Schlumberger M, Salvatore D.
    Curr Oncol; 2021 Dec 16; 28(6):5401-5407. PubMed ID: 34940089
    [Abstract] [Full Text] [Related]

  • 14. Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma.
    Chen TY, Lorch JH, Wong KS, Barletta JA.
    Histopathology; 2020 Aug 16; 77(2):314-320. PubMed ID: 32428249
    [Abstract] [Full Text] [Related]

  • 15. First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study.
    Soll D, Bischoff P, Frisch A, Jensen M, Karadeniz Z, Mogl MT, Horst D, Penzkofer T, Spranger J, Keilholz U, Mai K.
    BMC Endocr Disord; 2024 Feb 22; 24(1):25. PubMed ID: 38383419
    [Abstract] [Full Text] [Related]

  • 16. Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer - Real-World Outcomes From UK Centres.
    Lorimer C, Cheng L, Chandler R, Garcez K, Gill V, Graham K, Grant W, Sardo Infirri S, Wadsley J, Wall L, Webber N, Wong KH, Newbold K.
    Clin Oncol (R Coll Radiol); 2023 Jan 22; 35(1):e60-e66. PubMed ID: 36379836
    [Abstract] [Full Text] [Related]

  • 17. Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors.
    Cabanillas ME, Dadu R, Iyer P, Wanland KB, Busaidy NL, Ying A, Gule-Monroe M, Wang JR, Zafereo M, Hofmann MC.
    Thyroid; 2020 Sep 22; 30(9):1288-1296. PubMed ID: 32216548
    [Abstract] [Full Text] [Related]

  • 18. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
    Fallahi P, Ferrari SM, La Motta C, Materazzi G, Bocci G, Da Settimo F, Miccoli P, Antonelli A.
    Endocrine; 2016 Jul 22; 53(1):136-44. PubMed ID: 26286966
    [Abstract] [Full Text] [Related]

  • 19. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.
    Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas ME.
    J Immunother Cancer; 2018 Jul 11; 6(1):68. PubMed ID: 29996921
    [Abstract] [Full Text] [Related]

  • 20. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
    Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B.
    J Clin Oncol; 2018 Jan 01; 36(1):7-13. PubMed ID: 29072975
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.